Latest Quinolines Stories

SAN DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) securities has filed a complaint in the U.S. District Court for the District of Massachusetts. The complaint alleges that Aveo and certain of its officers violated the Securities Exchange Act of 1934 (the "Exchange Act") between January 3, 2012 and May 1, 2013 (the "Class Period"). (Logo:...

Drugs Include Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate® CARY, N.C., April 5, 2013 /PRNewswire/ -- Covis Pharmaceuticals, Inc. announced an agreement today to distribute Nilandron(®) (nilutamide), Plaquenil(®) (hydroxychloroquine), Rilutek(®) (riluzole), Uroxatral(®) (alfuzosin hydrochloride) and Kayexalate(®) (sodium polystyrene sulfate) in the United States.The products cover a broad array of treatments and disease states: Nilandron is used to treat...

Drug may be major advance as malaria has developed resistance to existing treatments Scientists at Oregon Health & Science University and the Portland VA Medical Center have developed a drug that may represent one of the world's best hopes for treating and preventing malaria — a disease that kills more than one million people each year. The scientists have described the drug, and its effectiveness against mice infected with malaria, in the March 20 issue of Science Translational...

Early diagnosis and treatment with antimalarial drugs (ACTs—artemisinin based combination treatments) has been linked to a reduction in malaria in the migrant population living on the Thai-Myanmar border, despite evidence of increasing resistance to ACTs in this location, according to a study by international researchers published in this week's PLOS Medicine. These findings are important as this study suggests that alternative treatments are urgently needed to replace the failing first...

Researchers at Karolinska Institutet in Sweden have found an explanation for why the level of kynurenic acid (KYNA) is higher in the brains of people with schizophrenia or bipolar disease with psychosis. The study, which is published in the scientific periodical Molecular Psychiatry, identifies a gene variant associated with an increased production of KYNA. The discovery contributes to the further understanding of the link between inflammation and psychosis – and might pave the way for...

ALISO VIEJO, Calif., Nov. 27, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary results for the quarter ended September 30, 2012. Financial Update Based on preliminary results for the fourth fiscal quarter ended September 30, 2012, Avanir estimates: Gross revenue for NUEDEXTA® of $15.4 million, representing an increase of approximately 26% over the prior quarter Total operating expenses, excluding cost of product sales and non-cash...

In malaria-endemic countries, 350 million people are predicted to be deficient in an enzyme that means they can suffer severe complications from taking primaquine, a key drug for treating relapsing malaria, according to a study funded by the Wellcome Trust and published in this week's PLOS Medicine. This finding is important as primaquine is recommended in the global action plan to eliminate malaria and is the only drug to prevent malaria relapse. The benefits of implementing a treatment...

Malaria-drug monitoring over the past 30 years has shown that malaria parasites develop resistance to medicine, and the first signs of resistance to the newest drugs have just been observed. At the same time, resistance monitoring at the University of Copenhagen shows that the previously efficacious drug chloroquine is once again beginning to work against malaria. In time that will ensure cheaper treatment for the world’s poor. Scientists and healthcare personnel the world over fear that...

Scientists at The University of Nottingham say adverse side-effects caused by the anti-parasitic drug quinine in the treatment of malaria could be controlled by what we eat. The research, carried out by Nottingham scientists on the University’s campuses in the UK and Malaysia, indicates that natural variation in our levels of the amino acid, tryptophan, has a marked bearing on how we respond to quinine treatment. It appears that the lower our levels of tryptophan the more likely it is...

RARITAN, N.J., Sept. 5, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy. The FDA grants priority review to medicines that may offer major advances in care or provide a treatment option where no adequate...